{"id":949216,"date":"2026-04-06T16:35:10","date_gmt":"2026-04-06T20:35:10","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/ultragenyx-pharmaceutical-inc-class-action-levi-korsinsky-reminds-ultragenyx-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-april-6-2026-rare\/"},"modified":"2026-04-06T16:35:10","modified_gmt":"2026-04-06T20:35:10","slug":"ultragenyx-pharmaceutical-inc-class-action-levi-korsinsky-reminds-ultragenyx-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-april-6-2026-rare","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/ultragenyx-pharmaceutical-inc-class-action-levi-korsinsky-reminds-ultragenyx-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-april-6-2026-rare\/","title":{"rendered":"Ultragenyx Pharmaceutical Inc. Class Action: Levi &amp; Korsinsky Reminds Ultragenyx Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 6, 2026 \u2013 RARE"},"content":{"rendered":"<div class=\"mw_release\">\n<p>NEW YORK, April  06, 2026  (GLOBE NEWSWIRE) &#8212; Levi &amp; Korsinsky, LLP notifies investors in\u00a0<strong>Ultragenyx Pharmaceutical Inc.<\/strong> (&#8220;Ultragenyx&#8221; or the &#8220;Company&#8221;) (NASDAQ: RARE) of a class action securities lawsuit.<\/p>\n<p>\n        <strong>CLASS DEFINITION: <\/strong>The lawsuit seeks to recover losses on behalf of Ultragenyx investors who were adversely affected by alleged securities fraud between August 3, 2023 and December 26, 2025. Follow the link below to get more information and be contacted by a member of our team:<\/p>\n<p align=\"center\">\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=EtCzAJD7AmS4eqEifRWu7zafrU-45-m1BQn7VmljPbWF-p6SUiGDqLTLhcYPjD4g2UhWBd3l3kICxbeyBH6bq0e5uMly3SrsgURvA1dzilx0yPsPGSs803GwfzdZEPQCmNHVm4FO7h_UJklnie3A_Jc5YCKPYTEBU8Zh7_XNCDDT2Z4zxX9VZYAyYKLFGR9KNhUlJoxLIO0HkxTdVplrWghGIqicXsmJjskIkLo7zvHNfaUtJUoof8qB4I7qpzpbh8L4FPeHYHprjwA0rH17oC1uZ2e04asgzCvO2wDEuFwjjr1DgrRiQV_0H9gtKK8A\" rel=\"nofollow\" target=\"_blank\">https:\/\/zlk.com\/pslra-1\/ultragenyx-pharmaceutical-inc-lawsuit-submission-form-2?prid=185169&amp;wire=3<\/a>\n      <\/p>\n<p>\n        <strong>RARE<\/strong> investors may also contact Joseph E. Levi, Esq. via email at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=SUetFB_2EkX97q3Z36xma13brPD-ESGgLbec3_YhuKbAh3N-_vynbBdWxpQQWIX0151h19rbvUji0WEczWo3uRzU5m6dcBbMI_u0liNUYOo=\" rel=\"nofollow\" target=\"_blank\">jlevi@levikorsinsky.com<\/a>\u00a0or by telephone at (212) 363-7500.<\/p>\n<p>\n        <strong>CASE DETAILS: <\/strong>According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and\/or concealing material adverse facts concerning the true state of setrusumab\u2019s potential and the true risk inherent in the study protocols put forth; notably, that, while setrusumab does increase material bone density, this increase does not correlate to a decrease in annualized fracture rates or otherwise the Phase III Orbit and Cosmic studies were much less likely to be able to demonstrate such a link than management claimed. On December 29, 2025, Ultragenyx announced that both its Phase III Orbit and Cosmic Studies had not \u201cachieved statistical significance against the primary endpoints of reduction in annualized clinical fracture rate compared to placebo or bisphosphonates, respectively.\u201d The Company attributed the study failure to a \u201clow fracture rate in the placebo group\u201d of Orbit and a trend that fell shy of statistical significance in Cosmic. Following this news, the price of Ultragenyx\u2019s common stock declined dramatically. From a closing market price of $34.19 per share on December 26, 2025, Ultragenyx\u2019s stock price fell to $19.72 per share on December 29, 2025, a decline of about 42.32% in the span of just a single day.<\/p>\n<p>\n        <strong>WHAT&#8217;S NEXT? <\/strong>If you suffered a loss in Ultragenyx during the relevant time frame, you have until <strong>April 6, 2026<\/strong>\u00a0to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn&#8217;t require that you serve as a lead plaintiff.<\/p>\n<p>\n        <strong>NO COST TO YOU: <\/strong>If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. <strong>There is no cost or obligation to participate.<\/strong><\/p>\n<p>\n        <strong>WHY LEVI &amp; KORSINSKY: <\/strong>Over the past 20 years, the team at Levi &amp; Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi &amp; Korsinsky has ranked in ISS Securities Class Action Services\u2019 Top 50 Report as one of the top securities litigation firms in the United States.<\/p>\n<p>\n        <strong>CONTACT:<\/strong><br \/>\n        <br \/>Levi &amp; Korsinsky, LLP <br \/>Joseph E. Levi, Esq.<br \/>Ed Korsinsky, Esq.<br \/>33 Whitehall Street, 27th Floor<br \/>New York, NY 10004<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=SUetFB_2EkX97q3Z36xma13brPD-ESGgLbec3_YhuKb9-USBVg2-WXq45E9qc2dXiC3jJR-izRZnlyvs2j_zRXfQSBXmb9nJ0xxt7F3nyFE=\" rel=\"nofollow\" target=\"_blank\">jlevi@levikorsinsky.com<\/a><br \/>Tel: (212) 363-7500<br \/>Fax: (212) 363-7171<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=fyZ7MYXdycxQ3bVeU6nC29afM9raUvVehji5QS0wH6xFhUmhVU9m_vJ-hY2XB7MkwhoYxRLP5OMg-f3PPCK8jA==\" rel=\"nofollow\" target=\"_blank\">www.zlk.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4MzA4MSM3NTE2NTk3IzIwMjA0MjY=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NDUwNmZhOWItMzQxYS00ZTg2LTkzZWYtNTcwMDExMzA2NjQ3LTEwMzIyOTMtMjAyNi0wNC0wNi1lbg==\/tiny\/Levi-Korsinsky-LLP.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NEW YORK, April 06, 2026 (GLOBE NEWSWIRE) &#8212; Levi &amp; Korsinsky, LLP notifies investors in\u00a0Ultragenyx Pharmaceutical Inc. (&#8220;Ultragenyx&#8221; or the &#8220;Company&#8221;) (NASDAQ: RARE) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Ultragenyx investors who were adversely affected by alleged securities fraud between August 3, 2023 and December 26, 2025. Follow the link below to get more information and be contacted by a member of our team: https:\/\/zlk.com\/pslra-1\/ultragenyx-pharmaceutical-inc-lawsuit-submission-form-2?prid=185169&amp;wire=3 RARE investors may also contact Joseph E. Levi, Esq. via email at\u00a0jlevi@levikorsinsky.com\u00a0or by telephone at (212) 363-7500. CASE DETAILS: According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and\/or concealing material &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ultragenyx-pharmaceutical-inc-class-action-levi-korsinsky-reminds-ultragenyx-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-april-6-2026-rare\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Ultragenyx Pharmaceutical Inc. Class Action: Levi &amp; Korsinsky Reminds Ultragenyx Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 6, 2026 \u2013 RARE&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-949216","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Ultragenyx Pharmaceutical Inc. Class Action: Levi &amp; Korsinsky Reminds Ultragenyx Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 6, 2026 \u2013 RARE - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ultragenyx-pharmaceutical-inc-class-action-levi-korsinsky-reminds-ultragenyx-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-april-6-2026-rare\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ultragenyx Pharmaceutical Inc. Class Action: Levi &amp; Korsinsky Reminds Ultragenyx Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 6, 2026 \u2013 RARE - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, April 06, 2026 (GLOBE NEWSWIRE) &#8212; Levi &amp; Korsinsky, LLP notifies investors in\u00a0Ultragenyx Pharmaceutical Inc. (&#8220;Ultragenyx&#8221; or the &#8220;Company&#8221;) (NASDAQ: RARE) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Ultragenyx investors who were adversely affected by alleged securities fraud between August 3, 2023 and December 26, 2025. Follow the link below to get more information and be contacted by a member of our team: https:\/\/zlk.com\/pslra-1\/ultragenyx-pharmaceutical-inc-lawsuit-submission-form-2?prid=185169&amp;wire=3 RARE investors may also contact Joseph E. Levi, Esq. via email at\u00a0jlevi@levikorsinsky.com\u00a0or by telephone at (212) 363-7500. CASE DETAILS: According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and\/or concealing material &hellip; Continue reading &quot;Ultragenyx Pharmaceutical Inc. Class Action: Levi &amp; Korsinsky Reminds Ultragenyx Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 6, 2026 \u2013 RARE&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/ultragenyx-pharmaceutical-inc-class-action-levi-korsinsky-reminds-ultragenyx-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-april-6-2026-rare\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-06T20:35:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4MzA4MSM3NTE2NTk3IzIwMjA0MjY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ultragenyx-pharmaceutical-inc-class-action-levi-korsinsky-reminds-ultragenyx-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-april-6-2026-rare\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ultragenyx-pharmaceutical-inc-class-action-levi-korsinsky-reminds-ultragenyx-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-april-6-2026-rare\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Ultragenyx Pharmaceutical Inc. Class Action: Levi &amp; Korsinsky Reminds Ultragenyx Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 6, 2026 \u2013 RARE\",\"datePublished\":\"2026-04-06T20:35:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ultragenyx-pharmaceutical-inc-class-action-levi-korsinsky-reminds-ultragenyx-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-april-6-2026-rare\\\/\"},\"wordCount\":513,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ultragenyx-pharmaceutical-inc-class-action-levi-korsinsky-reminds-ultragenyx-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-april-6-2026-rare\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY4MzA4MSM3NTE2NTk3IzIwMjA0MjY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ultragenyx-pharmaceutical-inc-class-action-levi-korsinsky-reminds-ultragenyx-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-april-6-2026-rare\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ultragenyx-pharmaceutical-inc-class-action-levi-korsinsky-reminds-ultragenyx-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-april-6-2026-rare\\\/\",\"name\":\"Ultragenyx Pharmaceutical Inc. Class Action: Levi &amp; Korsinsky Reminds Ultragenyx Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 6, 2026 \u2013 RARE - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ultragenyx-pharmaceutical-inc-class-action-levi-korsinsky-reminds-ultragenyx-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-april-6-2026-rare\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ultragenyx-pharmaceutical-inc-class-action-levi-korsinsky-reminds-ultragenyx-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-april-6-2026-rare\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY4MzA4MSM3NTE2NTk3IzIwMjA0MjY=\",\"datePublished\":\"2026-04-06T20:35:10+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ultragenyx-pharmaceutical-inc-class-action-levi-korsinsky-reminds-ultragenyx-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-april-6-2026-rare\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ultragenyx-pharmaceutical-inc-class-action-levi-korsinsky-reminds-ultragenyx-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-april-6-2026-rare\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ultragenyx-pharmaceutical-inc-class-action-levi-korsinsky-reminds-ultragenyx-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-april-6-2026-rare\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY4MzA4MSM3NTE2NTk3IzIwMjA0MjY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY4MzA4MSM3NTE2NTk3IzIwMjA0MjY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ultragenyx-pharmaceutical-inc-class-action-levi-korsinsky-reminds-ultragenyx-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-april-6-2026-rare\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ultragenyx Pharmaceutical Inc. Class Action: Levi &amp; Korsinsky Reminds Ultragenyx Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 6, 2026 \u2013 RARE\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ultragenyx Pharmaceutical Inc. Class Action: Levi &amp; Korsinsky Reminds Ultragenyx Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 6, 2026 \u2013 RARE - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/ultragenyx-pharmaceutical-inc-class-action-levi-korsinsky-reminds-ultragenyx-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-april-6-2026-rare\/","og_locale":"en_US","og_type":"article","og_title":"Ultragenyx Pharmaceutical Inc. Class Action: Levi &amp; Korsinsky Reminds Ultragenyx Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 6, 2026 \u2013 RARE - Market Newsdesk","og_description":"NEW YORK, April 06, 2026 (GLOBE NEWSWIRE) &#8212; Levi &amp; Korsinsky, LLP notifies investors in\u00a0Ultragenyx Pharmaceutical Inc. (&#8220;Ultragenyx&#8221; or the &#8220;Company&#8221;) (NASDAQ: RARE) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Ultragenyx investors who were adversely affected by alleged securities fraud between August 3, 2023 and December 26, 2025. Follow the link below to get more information and be contacted by a member of our team: https:\/\/zlk.com\/pslra-1\/ultragenyx-pharmaceutical-inc-lawsuit-submission-form-2?prid=185169&amp;wire=3 RARE investors may also contact Joseph E. Levi, Esq. via email at\u00a0jlevi@levikorsinsky.com\u00a0or by telephone at (212) 363-7500. CASE DETAILS: According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and\/or concealing material &hellip; Continue reading \"Ultragenyx Pharmaceutical Inc. Class Action: Levi &amp; Korsinsky Reminds Ultragenyx Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 6, 2026 \u2013 RARE\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/ultragenyx-pharmaceutical-inc-class-action-levi-korsinsky-reminds-ultragenyx-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-april-6-2026-rare\/","og_site_name":"Market Newsdesk","article_published_time":"2026-04-06T20:35:10+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4MzA4MSM3NTE2NTk3IzIwMjA0MjY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ultragenyx-pharmaceutical-inc-class-action-levi-korsinsky-reminds-ultragenyx-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-april-6-2026-rare\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ultragenyx-pharmaceutical-inc-class-action-levi-korsinsky-reminds-ultragenyx-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-april-6-2026-rare\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Ultragenyx Pharmaceutical Inc. Class Action: Levi &amp; Korsinsky Reminds Ultragenyx Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 6, 2026 \u2013 RARE","datePublished":"2026-04-06T20:35:10+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ultragenyx-pharmaceutical-inc-class-action-levi-korsinsky-reminds-ultragenyx-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-april-6-2026-rare\/"},"wordCount":513,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ultragenyx-pharmaceutical-inc-class-action-levi-korsinsky-reminds-ultragenyx-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-april-6-2026-rare\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4MzA4MSM3NTE2NTk3IzIwMjA0MjY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ultragenyx-pharmaceutical-inc-class-action-levi-korsinsky-reminds-ultragenyx-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-april-6-2026-rare\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/ultragenyx-pharmaceutical-inc-class-action-levi-korsinsky-reminds-ultragenyx-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-april-6-2026-rare\/","name":"Ultragenyx Pharmaceutical Inc. Class Action: Levi &amp; Korsinsky Reminds Ultragenyx Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 6, 2026 \u2013 RARE - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ultragenyx-pharmaceutical-inc-class-action-levi-korsinsky-reminds-ultragenyx-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-april-6-2026-rare\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ultragenyx-pharmaceutical-inc-class-action-levi-korsinsky-reminds-ultragenyx-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-april-6-2026-rare\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4MzA4MSM3NTE2NTk3IzIwMjA0MjY=","datePublished":"2026-04-06T20:35:10+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ultragenyx-pharmaceutical-inc-class-action-levi-korsinsky-reminds-ultragenyx-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-april-6-2026-rare\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/ultragenyx-pharmaceutical-inc-class-action-levi-korsinsky-reminds-ultragenyx-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-april-6-2026-rare\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ultragenyx-pharmaceutical-inc-class-action-levi-korsinsky-reminds-ultragenyx-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-april-6-2026-rare\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4MzA4MSM3NTE2NTk3IzIwMjA0MjY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4MzA4MSM3NTE2NTk3IzIwMjA0MjY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ultragenyx-pharmaceutical-inc-class-action-levi-korsinsky-reminds-ultragenyx-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-april-6-2026-rare\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Ultragenyx Pharmaceutical Inc. Class Action: Levi &amp; Korsinsky Reminds Ultragenyx Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 6, 2026 \u2013 RARE"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/949216","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=949216"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/949216\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=949216"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=949216"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=949216"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}